WLM PHARMA

Active

Private limited companyfounded 2024active for 2 yearsEernegemweg 14, 8490 Jabbeke, BelgiumKBO/BCE: BE 1004.458.259

Summary

WLM PHARMA has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €58,427 and a net result of €27,289. Its solvency ranks better than 16% of 12,672 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 1.2% (low).

Risk analysisFollow Report Compare

WLM PHARMAActiveChecked score 65/100

Risk analysis Report Compare

History

On 9 January 2024, WLM PHARMA was incorporated as a private limited company by two natural persons, with a starting capital of €20,000.¹² WILLEMS PHARMA was merged into the company in 2025.³ Of the 2 current board members, Matthias Luyckx has served longest, since 2024.²

Acts, filings and financial milestones

All 5Gazette 3Filings 2

Next filing, financial year 2026, expected by 31-07-2027

2026

22-07

NBB filing Annual accounts filed

financial year 2025 · abbreviated format

2025

28-07

NBB filing Annual accounts filed

financial year 2024 · abbreviated format

03-01

Gazette deed Capital & shares · Name · Resignations & appointments · Restructuring

Resignation: WILLEMS Lore (director) · Appointment: WILLEMS Lore (director) · Merger16 facts ▸

General meeting, 09-12-2024 (2 times)
Merger, “ontbinding zonder vereffening, bestuursorganen van de betrokken vennootschappen” (deed in Dutch)
Shareholding
Accounting effect, 01-10-2024
Name change, WLM Pharma
Director resignation, WILLEMS Lore (director)
Director discharge, WILLEMS Lore (director)
Director appointment, WILLEMS Lore (director)
Other provision, “alle punten van de agenda binnen elke algemene vergadering, beraadslaging en stemming” (deed in Dutch)
Other provision, 24-10-2024 (2 times)
Other provision, “aanwezigheid aandeelhouders, alle aandeelhouders van beide vennootschappen aanwezig” (deed in Dutch)
Other provision, “verzaking terbeschikkingstelling stukken, voldoende ingelicht over geruisloze fusie” (deed in Dutch)
+4 further facts in this act

2024

05-11

Gazette deed Restructuring

Merger · Shareholding · Incorporation19 facts ▸

Merger, “volgens hierna vermelde voorwaarden, bestuursorganen van Luyckx Pharma BV en Willems Pharma BV in gezamenlijk overleg” (deed in Dutch)
Other provision, “wenselijkheid fusie, bestuursorganen van te fuseren vennootschappen” (deed in Dutch)
Shareholding, 100, “thans” (deed in Dutch)
Incorporation, 06-12-2022
Other provision, “statutenwijzigingen sinds oprichting, niet gewijzigd” (deed in Dutch) (2 times)
Registered office clause, “Heidelbergstraat 24A 0103,8210 Zedelgem” (deed in Dutch)
Other provision, “inschrijving rechtspersonenregister, Gent,afdeling Brugge” (deed in Dutch)
Board composition, Lore Willems (director (not named in the articles))
Incorporation, 09-01-2024
Registered office clause, “Eernegemweg 14,8490 Jabbeke” (deed in Dutch)
Board composition, Matthias Luyckx (director (not named in the articles))
Accounting effect, 01-10-2024
+7 further facts in this act

11-01

Gazette deed Incorporation

Appointment: Matthias Luyckx (director) · Founder · Registered office clause9 facts ▸

Incorporation, 09-01-2024
Founder, Matthias Luyckx
Registered office clause, “8490 Snellegem, Eernegemweg 14” (deed in Dutch)
Board rule, 1
Director appointment, Matthias Luyckx (director (not named in the articles))
Pre-incorporation commitments, “takeover, Alle verbintenissen en alle verplichtingen die eruit voortvloeien, en alle activiteiten ondernomen” (deed in Dutch)
Other provision, “UBO-register, De comparant erkent door de instrumenterende notaris te zijn gewezen op het UBO-register dat tot doel heeft toereikende, accurate en actuele infor…” (deed in Dutch)
Other provision, “UBO-register verplichting, De comparant verklaart op de hoogte te zijn van de verplichting in hoofde van de bestuurder(s) van de vennootschap om binnen de maand…” (deed in Dutch)
Founding capital, €20,000

Gazette deedNBB filing

3 of 3 deeds read